Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma

Oncology Reports

Volumn 12, Issue 6, 2004, Pages 1355-1364

  Hau, Peter ^a   Ruemmele, Petra ^b   Kunz Schughart, Leoni A ^b   Doerfelt, Anett ^a   Hirschmann, Birgit ^a   Lohmeier, Annette ^a   Koch, Horst ^a   Mueller, Adolf ^c   Bogdahn, Ulrich ^a   Bosserhoff, Anja Katrin ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Hospital Barmherzigen Brueder   (Germany)

Author keywords

High grade glioma; Melanoma inhibitory activity (MIA); MIA(splice); Time to progression

Indexed keywords

MIA PROTEIN, HUMAN; PROTEIN; SCLEROPROTEIN; TENASCIN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; BIOSYNTHESIS; BRAIN TUMOR; CELL CULTURE; CHILD; COMPARATIVE STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; WESTERN BLOTTING;

ADULT; AGED; ALTERNATIVE SPLICING; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELLS, CULTURED; CHILD; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TENASCIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 16644362274     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.6.1355     Document Type: Article

References (30)

1. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R and Bogdahn U: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54: 5695-5701, 1994. (Pubitemid 24346269)
2. Bosserhoff AK and Buettner R: Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol 17: 289-300, 2002.
3. Guba M, Bosserhoff AK, Steinbauer M, Abels C, Anthuber M, Buettner R and Jauch KW: Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Br J Cancer 83: 1216-1222, 2000.
4. Bosserhoff AK, Echtenacher B, Hein R and Buettner R: Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res 11: 417-421, 2001. (Pubitemid 32735233)
5. Bosserhoff AK, Stoll R, Sleeman JP, Bataille F, Buettner R and Holak TA: Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest 83: 1583-1594, 2003. (Pubitemid 37421099)
6. Bosserhoff AK, Hauschild A, Hein R, Schadendorf D, Stockflesh E, Bogenrieder T, Landthaier M, Buettner R and Stolz W: Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study. J Invest Dermatol 114: 395-396, 2000. (Pubitemid 30417780)
7. Hau P, Wise P, Bosserhoff AK, Blesch A, Jachimczak P, Tschertner I, Bogdahn U and Apfel R: Cloning and characterization of the expression pattern of a novel splice product MIA(splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP). J Invest Dermatol 119: 562-569, 2002.
8. Hau P, Apfel R, Wiese P, Tschertner I, Blesch A and Bogdahn U: Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin. Anticancer Res 22: 577-837, 2002.
9. Gladson CL: The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58: 1029-1040, 1999.
10. Uhm JH, Gladson CL and Rao JS: The role of integrins in the malignant phenotype of gliomas. Front Biosci 4: D188-199, 1999.
11. Goldbrunner RH, Bernstein JJ and Tonn JC: Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir 141: 295-305, 1999. (Pubitemid 29137544)
12. Tonn JC and Goldbrunner R: Mechanisms of glioma cell invasion. Acta Neurochir SuppI 88: 163-167, 2003.
13. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P and Weis S: Expression of Tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma, Cancer 98: 2430-2439, 2003. (Pubitemid 37466658)
14. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjogren HO and Widegren B: Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89: 251-258, 2000. (Pubitemid 30430741)
15. Jennings MT, Maciunas RJ, Carver R, Bascom CC, Juneau P, Misulis K and Moses HL: TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int J Cancer 49: 129-139, 1991.
16. Platten M, Wick W and Weller M: Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52: 401-410, 2001. (Pubitemid 32167828)
17. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J and Martin R: Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49: 5358-5363, 1989. (Pubitemid 19240474)
18. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W and Buettner: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57: 3149-3153, 1997.
19. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc pp457-481, 1958.
20. Siegel S and Castellan NJ: Measures of association and their tests of significance. In: Nonparametric Statistics for the Behavioural Sciences. McGraw-Hill, NY, pp234-312, 1988.
21. Wilhelm J and Pingoud A: Real-time polymerase chain reaction. Chem Biochem 4: 1120-1128, 2003.
22. Rossi ML, Jones NR, Candy E, Nicoll JA, Compton JS, Hughes JT, Esiri MM, Moss TH, Cruz-Sanchez FF and Coakham HB: The mononuclear cell infiltrate compared with survival in high-grade astrocytomas. Acta Neuropathol 78: 189-193, 1989. (Pubitemid 19160923)
23. Ware ML, Berger MS and Binder DK: Molecular biology of glioma tumorigenesis. Histol Histopathol 18: 207-216, 2003. (Pubitemid 36040462)
24. Mastronardi L, Guiducci A, Puzzilli F and Ruggeri A: Relationship between Ki-67 labeling index and survival in high-grade glioma patients treated after surgery with tamoxifen. J Neurosurg Sci 43: 263-270, 1999. (Pubitemid 30322189)
25. Balesaria S, Brock C, Bower M, Clark J, Nicholson SK, Lewis P, de Sanctis S, Evans H, Peterson D, Mendoza N, Glaser MG, Newlands ES and Fisher RA: Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br J Cancer 81: 1371-1377, 1999.
26. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG and Louis DN: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7: 839-845, 2001. (Pubitemid 32708719)
27. Prud'homme GJ and Piccirillo CA: The inhibitory effects of transforming growth factor-beta-1 (TGF-betal) in autoimmune diseases. J Autoimmun 14: 23-42, 2000. (Pubitemid 30080536)
28. Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K and Tonn JC: Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol 44: 23-33, 1999. (Pubitemid 29515646)
29. Tews DS and Nissen A: Of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis 18: 271-284, 1998-1999. (Pubitemid 30223703)
30. Rooprai HK, Vanmeter T, Panou C, Schnull S, Trillo-Pazos G, Davies D and Pilkington GJ: The role of integrin receptors in aspects of glioma invasion in vitro. Int J Dev Neurosci 17: 613-623, 1999. (Pubitemid 29421847)